Venture Capitalists Freeze Funding For Some U.S. Start-ups, But Could Channel More Investment Into China Health Care
This article was originally published in PharmAsia News
Executive Summary
BEIJING - While the Western world's financial maelstrom is already choking off funding for some biotech start-ups in the U.S., it could have the opposite effect in China, and trigger the flow of more capital into promising Chinese healthcare outfits, according to a partner in a half-billion-dollar venture capital firm